Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Developing drugs for use before, during and soon after percutaneous coronary intervention.

Gargiulo G, Moschovitis A, Windecker S, Valgimigli M.

Expert Opin Pharmacother. 2016;17(6):803-18. doi: 10.1517/14656566.2016.1145666. Epub 2016 Mar 3. Review.

PMID:
26800365
2.

Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting.

Verheugt FW.

JACC Cardiovasc Interv. 2015 Dec 21;8(14):1890-2. doi: 10.1016/j.jcin.2015.08.019. No abstract available.

PMID:
26718519
3.

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.

O'Connor SA, Amour J, Mercadier A, Martin R, Kerneis M, Abtan J, Brugier D, Silvain J, Barthélémy O, Leprince P, Montalescot G, Collet JP; ACTION Study Group.

Circ Cardiovasc Interv. 2015 Nov;8(11):e002786. doi: 10.1161/CIRCINTERVENTIONS.115.002786.

PMID:
26553698
4.

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D; PLATO Investigators.

J Am Heart Assoc. 2015 Oct 9;4(10):e002490. doi: 10.1161/JAHA.115.002490.

5.

Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.

Gan XD, Wei BZ, Fang D, Fang Q, Li KY, Ding SL, Peng S, Wan J.

Curr Med Res Opin. 2015 Dec;31(12):2313-23. doi: 10.1185/03007995.2015.1098600. Epub 2015 Nov 4. Review.

PMID:
26402735
6.

Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.

Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T.

Circ J. 2015;79(11):2452-60. doi: 10.1253/circj.CJ-15-0112. Epub 2015 Sep 16.

7.

[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].

Lalor N, Rodríguez L, Elissamburu P, Filipini E, Conde D, Nau G, Cura F, Trivi M.

Medicina (B Aires). 2015;75(4):207-12. Spanish.

8.

Antiplatelet therapy in acute coronary syndromes.

Grove EL, Würtz M, Thomas MR, Kristensen SD.

Expert Opin Pharmacother. 2015;16(14):2133-47. doi: 10.1517/14656566.2015.1079619. Epub 2015 Aug 17. Review.

PMID:
26293612
9.

Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.

Franchi F, Rollini F, Park Y, Angiolillo DJ.

Prog Cardiovasc Dis. 2015 Nov-Dec;58(3):267-77. doi: 10.1016/j.pcad.2015.08.009. Epub 2015 Aug 13. Review.

PMID:
26277706
10.

Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.

Dash D.

Cardiovasc Hematol Agents Med Chem. 2015;13(1):40-9. Review.

PMID:
26245659
11.

Practical experience with ticagrelor: an Australian and New Zealand perspective.

Harding SA, Van Gaal WJ, Schrale R, Gunasekara A, Amerena J, Mussap CJ, Aylward PE.

Curr Med Res Opin. 2015 Aug;31(8):1469-77. doi: 10.1185/03007995.2015.1058247. Epub 2015 Jun 30. Review.

PMID:
26086451
12.

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, Becker RC; PLATO Investigators.

Am Heart J. 2015 Jun;169(6):899-905.e1. doi: 10.1016/j.ahj.2015.03.015. Epub 2015 Mar 31.

13.

Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.

Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, Zettler ME, Baker BA, Fonarow GC, Peterson ED.

Circulation. 2015 Jul 21;132(3):174-81. doi: 10.1161/CIRCULATIONAHA.114.014992. Epub 2015 May 20.

14.

Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.

Monitillo F, Iacoviello M, Caldarola P, Valle R, Chiatto M, Aspromonte N.

Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):977-93. doi: 10.1517/17425255.2015.1037279. Epub 2015 Apr 16.

PMID:
25882759
15.

New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents.

Rahman A, Latona J.

Aust Fam Physician. 2014 Dec;43(12):861-6. Review.

PMID:
25705736
16.

Ticagrelor: a review of its use in adults with acute coronary syndromes.

Dhillon S.

Am J Cardiovasc Drugs. 2015 Feb;15(1):51-68. doi: 10.1007/s40256-015-0108-5. Review.

PMID:
25672642
17.

Bivalirudin for acute coronary syndromes: premises, promises and doubts.

Capodanno D, De Caterina R.

Thromb Haemost. 2015 Apr;113(4):698-707. doi: 10.1160/TH14-09-0765. Epub 2014 Dec 18. Review.

PMID:
25519159
18.

Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.

Braun OÖ, Bico B, Chaudhry U, Wagner H, Koul S, Tydén P, Scherstén F, Jovinge S, Svensson PJ, Gustav Smith J, van der Pals J.

Thromb Res. 2015 Jan;135(1):26-30. doi: 10.1016/j.thromres.2014.10.016. Epub 2014 Oct 24.

PMID:
25467434
19.

SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?

Delesque-Touchard N, Pflieger AM, Bonnet-Lignon S, Millet L, Salel V, Boldron C, Lassalle G, Herbert JM, Savi P, Bono F.

Thromb Res. 2014 Sep;134(3):693-703. doi: 10.1016/j.thromres.2014.06.034. Epub 2014 Jul 11.

PMID:
25064036
20.

Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.

Turpie AG.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):963-76. doi: 10.1586/14779072.2014.938055. Epub 2014 Jul 12. Review.

PMID:
25017622
Items per page

Supplemental Content

Loading ...
Write to the Help Desk